Early interferon therapy reduces secondary myelofibrosis risk in young ET and PV patients. Cytoreductive drugs do not lower thrombotic event risk in young patients. Elevated white blood cell counts ...

A growing body of research has identified a hidden immune defect, not written in DNA, that helps explain why certain people ...

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Interferon-α nasal spray was safe and effective in reducing COVID-19 risk by 40% in patients with cancer, demonstrating its potential as an additional preventive strategy alongside vaccines and ...

An immune system defect makes affected individuals vulnerable to severe viral diseases such as influenza or COVID-19. It is caused by the body's own antibodies, which inhibit important defense ...

CHICAGO — The use of a clinically validated flow cytometry test can assess type 1 and type 2 interferon activity in children with various pediatric inflammatory diseases to evaluate and monitor their ...

Interferon signatures may be a candidate biomarker for early identification of response to lupus nephritis induction treatment. Persistent type I interferon-driven transcriptional activity in ...

Researchers from Mount Sinai have uncovered a possible explanation for why a flu infection can lead to heart disease. They’ve shown from work with mouse models and human data how the immune system ...